MedTrace Logo

A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer

NCT00214864 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-02-14

No results posted yet for this study

Summary

The purpose of this study is to attempt to find better tolerated doses and schedules of this highly effective combination chemotherapy regimen.

Conditions

Interventions

DRUG

docetaxel, capecitabine

cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8

Sponsors & Collaborators

Principal Investigators

  • Charles L Vogel, MD · Cancer Research Network, Inc

  • Elizabeth Tan-Chiu, MD · Cancer Research Network, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214864 on ClinicalTrials.gov